GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which ...

The GLP-1 receptor agonists decrease HbA 1c by stimulating glucose-dependent insulin secretion and by reducing glucagon secretion, gastric emptying, and appetite. 4,5 GLP-1 receptor agonist treatment ...

The GLP-1 RA (liraglutide 3.0 mg) and placebo are provided by Novo Nordisk. Cambridge weight plan diet products for the initial 8 weeks weight loss programme are provided by Cambridge weight plan. JRL ...

The HR was 0·97 (95% CI 0·9–1·0) after 0–8 years and 1·40 (95% CI 1·1–1·7) after 8–10 years of follow-up, respectively (Table S12, Figure S3). Among patients who discontinued within the first 2 years, ...

Understanding the GLP-1 consumer. Getting to know GLP-1 consumers is becoming a high priority for the food and beverage industry, as their numbers rise and buying power grows. Now a new report from ...

GLP-1 receptor agonist users had a significant 39% higher risk of requiring KRT (95% CI, 1.19-1.63) compared with SGLT2 inhibitor users, Dr Chang’s team reported in the American Journal of ...

Patients with moderate peripheral artery disease (PAD) who used glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have more favorable outcomes, including fewer cardiovascular (CV) events and major ...

People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported June 10 in the journal Obesity.. That’s far less than the 15% to 21% body ...